Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor Toxicity
Immune checkpoint inhibitors (ICIs) are a class of drug that produces durable and sustained anti-tumour responses in a wide variety of malignancies. The exponential rise in their use has been mirrored by a rise in immune-related adverse events (IrAEs). Knowledge of such toxicities, as well as effect...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/30/7/502 |
| _version_ | 1827733376761593856 |
|---|---|
| author | Christopher Cluxton Jarushka Naidoo |
| author_facet | Christopher Cluxton Jarushka Naidoo |
| author_sort | Christopher Cluxton |
| collection | DOAJ |
| description | Immune checkpoint inhibitors (ICIs) are a class of drug that produces durable and sustained anti-tumour responses in a wide variety of malignancies. The exponential rise in their use has been mirrored by a rise in immune-related adverse events (IrAEs). Knowledge of such toxicities, as well as effective management algorithms for these toxicities, is essential to optimize clinical efficacy and safety. Currently, the guidelines for management of the IrAEs are based largely on retrospective studies and case series. In this article, we review the current landscape of clinical trials investigating the management of IrAEs with an aim to develop standardised, randomised controlled trial-based management algorithms for ICI-related toxicities. |
| first_indexed | 2024-03-11T01:09:34Z |
| format | Article |
| id | doaj.art-40fea4908307449592785254f94988d1 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-11T01:09:34Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-40fea4908307449592785254f94988d12023-11-18T18:56:10ZengMDPI AGCurrent Oncology1198-00521718-77292023-07-013076862687110.3390/curroncol30070502Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor ToxicityChristopher Cluxton0Jarushka Naidoo1Beaumont Hospital, RCSI Cancer Centre, D09 V2N0 Dublin, IrelandBeaumont Hospital, RCSI Cancer Centre, D09 V2N0 Dublin, IrelandImmune checkpoint inhibitors (ICIs) are a class of drug that produces durable and sustained anti-tumour responses in a wide variety of malignancies. The exponential rise in their use has been mirrored by a rise in immune-related adverse events (IrAEs). Knowledge of such toxicities, as well as effective management algorithms for these toxicities, is essential to optimize clinical efficacy and safety. Currently, the guidelines for management of the IrAEs are based largely on retrospective studies and case series. In this article, we review the current landscape of clinical trials investigating the management of IrAEs with an aim to develop standardised, randomised controlled trial-based management algorithms for ICI-related toxicities.https://www.mdpi.com/1718-7729/30/7/502cancer immunotherapytumour immunologyclinical trialsadverse effects |
| spellingShingle | Christopher Cluxton Jarushka Naidoo Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor Toxicity Current Oncology cancer immunotherapy tumour immunology clinical trials adverse effects |
| title | Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor Toxicity |
| title_full | Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor Toxicity |
| title_fullStr | Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor Toxicity |
| title_full_unstemmed | Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor Toxicity |
| title_short | Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor Toxicity |
| title_sort | prospective clinical trials to advance the study of immune checkpoint inhibitor toxicity |
| topic | cancer immunotherapy tumour immunology clinical trials adverse effects |
| url | https://www.mdpi.com/1718-7729/30/7/502 |
| work_keys_str_mv | AT christophercluxton prospectiveclinicaltrialstoadvancethestudyofimmunecheckpointinhibitortoxicity AT jarushkanaidoo prospectiveclinicaltrialstoadvancethestudyofimmunecheckpointinhibitortoxicity |